Home > Newsletters > FDAnews Drug Daily Bulletin > Pfizer Reports Second Phase III Failure in a Week: Torisel, Bevacizumab Combo for Advanced RCC
FDAnews Drug Daily Bulletin
Aug. 14, 2012 | Vol. 9 No. 159
Pfizer Reports Second Phase III Failure in a Week: Torisel, Bevacizumab Combo for Advanced RCC
In the second late-stage failure for Pfizer this week, the company saw disappointing results for its Torisel when combined with Roche’s Avastin as a first-line treatment for advanced renal cell carcinoma (RCC). The trial, which pitted the combo against Avastin (bevacizumab) plus interferon-alfa-2a (IFN-α-2a), did not show superiority in extending progression free survival (PFS). Pfizer is analyzing additional efficacy endpoints and safety data, it said.
Drug Industry Daily
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.